EUVIMEDEUVIMED entdecken
Crossref

Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?

Christelle Boglione-Kerrien iD, Florian Lemaitre iD, Elodie Gautier-Veyret iD, Sarah Baklouti, Anne Hulin, Muriel Cornet, Françoise Botterel, Jeff Morcet, Audrey Le Bot, Marie-Clémence Verdier iD, Jean-Pierre Gangneux iD, Hélène Guegan

Journal of Antimicrobial Chemotherapy · 02.07.2026 · 81 (8)

DOI: 10.1093/jac/dkag231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 22.07.2026. Verfasst von Christelle Boglione-Kerrien und 11 weiteren Autor:innen. Beteiligte Einrichtung: CHU Rennes, Laboratory of Biological Pharmacology, Rennes, France. Hauptthemen laut MEDLINE: Voriconazole, Antifungal Agents, Urinary Tract Infections, Candida. Die Arbeit nennt 47 Literaturangaben. Gefördert von: French Society of Medical Mycology (SFMM), French Society of Pharmacology and Therapeutics (SFPT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treating Candida spp. urinary tract infections (UTIs) are challenging when isolates have reduced susceptibility to fluconazole. Voriconazole may be a therapeutic alternative despite its low urinary excretion as an unchanged compound.

Objectives

To quantify voriconazole and its main metabolite, voriconazole N-oxide, in urine and plasma, determine minimum inhibitory concentrations (MICs) of voriconazole and voriconazole N-oxide, and assess the antifungal activity of urine from voriconazole-treated patients.

Methods

Sixty patients receiving oral voriconazole were prospectively included. Voriconazole and voriconazole N-oxide concentrations in urine (12-h urine volume) and plasma were measured by liquid chromatography-tandem mass spectrometry. MICs were determined by broth microdilution according to EUCAST guidelines. Urinary antifungal activity was assessed using a disk diffusion bioassay, including against N. glabratus. A pharmacokinetic/pharmacodynamic target concentration/MIC >1 in urine was defined.

Results

Median voriconazole urinary concentration was 1.9 mg/L [1.1–3.1], similar to plasma trough concentration (2.2 mg/L) and positively correlated (R2 = 0.82). Voriconazole N-oxide urinary concentrations (median 20.4 mg/L) were substantially higher than plasma trough concentrations (median 2.1 mg/L). Voriconazole MICs ranged from 0.155 to 0.75 mg/L, while voriconazole N-oxide MICs were 32–48 mg/L for reduced susceptibility to fluconazole isolates. Urine with voriconazole concentrations above 3 mg/L was more likely to inhibit N. glabratus. The median urinary voriconazole concentration/MIC ratio of 4.75 supports potential clinical efficacy.

Conclusions

Voriconazole can achieve therapeutically relevant urinary concentrations for treating UTIs with reduced susceptibility to fluconazole. Therapeutic drug monitoring may facilitate individualized dosing and optimize treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleAntifungal AgentsUrinary Tract InfectionsCandidaCandidiasisHumansMicrobial Sensitivity TestsFemaleMaleProspective StudiesFluconazoleMiddle AgedAgedAdultPlasmaDrug Resistance, FungalAged, 80 and overUrineChromatography, Liquid

Substanzen

VoriconazoleAntifungal AgentsFluconazole

Autor:innen und Institutionen

  • CHU Rennes, Laboratory of Biological Pharmacology, Rennes, France.
  • Univ Rennes, CHU de Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
  • Univ. Grenoble Alpes, INSERM U1300, HP2 Laboratory, Grenoble, France.
  • Univ. Grenoble Alpes, CHU Grenoble Alpes, Laboratoire de Pharmacologie, Pharmacogénétique et Toxicologie, Grenoble, France.
  • Pharmacokinetics and Toxicology Laboratory, Federative Institute of Biology, Toulouse University Hospital, Toulouse, France.
  • INTHERES, University of Toulouse, INRAE, ENVT, Toulouse, France.

ORCID-Profile: Christelle Boglione-Kerrien, Florian Lemaitre, Elodie Gautier-Veyret, Marie-Clémence Verdier, Jean-Pierre Gangneux

Förderung

  • French Society of Medical Mycology (SFMM)
  • French Society of Pharmacology and Therapeutics (SFPT)

Zitieren

APA

Boglione-Kerrien, C., Lemaitre, F., Gautier-Veyret, E., Baklouti, S., Hulin, A., Cornet, M., Botterel, F., Morcet, J., Le Bot, A., Verdier, M. C., Gangneux, J. P., & Guegan, H. (2026). Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?. Journal of Antimicrobial Chemotherapy, 81(8). https://doi.org/10.1093/jac/dkag231

Vancouver

Boglione-Kerrien C, Lemaitre F, Gautier-Veyret E, Baklouti S, Hulin A, Cornet M, et al. Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?. Journal of Antimicrobial Chemotherapy. 2026;81(8). doi:10.1093/jac/dkag231

BibTeX
@article{BoglioneKerrien2026,
  author = {Boglione-Kerrien, Christelle and Lemaitre, Florian and Gautier-Veyret, Elodie and Baklouti, Sarah and Hulin, Anne and Cornet, Muriel and Botterel, Françoise and Morcet, Jeff and Le Bot, Audrey and Verdier, Marie-Clémence and Gangneux, Jean-Pierre and Guegan, Hélène},
  title = {Can pharmacokinetic/pharmacodynamic targets be achieved with voriconazole in the treatment of urinary tract infections caused by Candida spp. with reduced susceptibility to fluconazole?},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {8},
  doi = {10.1093/jac/dkag231}
}
Kostenlos starten →